Core Insights - Insulet Corporation (PODD) reported second-quarter adjusted earnings of $1.17 per share, surpassing the consensus estimate of 92 cents [1] - The company achieved sales of $649.1 million, reflecting a year-over-year increase of 32.9% (31.3% in constant currency), exceeding the consensus of $612.22 million [1] Revenue Breakdown - Total Omnipod revenue reached $639 million, up 33.0% year-over-year, or 31.4% in constant currency [2] - U.S. Omnipod revenue was $453.2 million, an increase of 28.7%, while International Omnipod revenue was $185.8 million, up 45% (38.8% in constant currency) [2] - Drug Delivery revenue amounted to $10.2 million [2] Profitability Metrics - Gross margin improved to 69.7%, up 190 basis points from the prior year [3] - Operating income was $121.1 million, representing 18.7% of revenue, an increase of 750 basis points year-over-year [3] - Adjusted EBITDA reached $157.5 million, or 24.3% of revenue, up 570 basis points from the previous year [3] Future Guidance - For 2025, Insulet expects revenue growth between 24% and 27%, an increase from the prior range of 19%-22% [4] - The company raised its fiscal 2025 sales guidance to $2.57 billion-$2.63 billion, compared to the previous range of $2.47 billion-$2.53 billion [4] - Omnipod sales are projected to increase by 25%-28%, up from the previous estimate of 20%-23% [4] Third Quarter Forecast - Insulet forecasts third-quarter revenue growth between 22%-25%, with U.S. Omnipod sales expected to rise by 21%-24% and International Omnipod sales by 33%-36% [5] - Projected third-quarter sales are estimated at $663.56 million-$679.88 million, exceeding the consensus of $645.86 million [5] Market Adoption - Over 25,000 healthcare providers are now prescribing Omnipod 5 in the U.S., marking a 20% increase from the previous year [6] - Insulet's stock price increased by 4.55% to $289.91 at the time of publication [6]
Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5